KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV) Revenue
Annual & quarterly revenue history · segment & region breakdown
KALV · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsKalVista Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.12B, an increase of 0.00% year-over-year from $0.07B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.07B | +$0.07B | — |
| 2025-04-30 | $0.00B | +$0.00B | — |
| 2024-04-30 | $0.00B | +$0.00B | — |
| 2023-04-30 | $0.00B | +$0.00B | — |
| 2022-04-30 | $0.00B | +$0.00B | — |
| 2021-04-30 | $0.00B | -$0.01B | -100.00% |
| 2020-04-30 | $0.01B | -$0.00B | -21.31% |
| 2019-04-30 | $0.02B | +$0.01B | +92.13% |
| 2018-04-30 | $0.01B | +$0.01B | +458.11% |
| 2017-04-30 | $0.00B | -$0.00B | -29.49% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income KalVista Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
KalVista Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from KalVista Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KALV revenue · 4 questionsKALV's trailing twelve-month (TTM) revenue is $0.12B. That is an increase of 0.00% year-over-year from $0.07B in FY2025.
▸ Source: FMP · KalVista Pharmaceuticals, Inc. SEC filings · GAAP · KalVista Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026